Want to join the conversation?
$AMGN said that the US FDA has approved the Repatha (evolocumab) Pushtronex system, a new, monthly single-dose administration option. Repatha, which is a cholesterol-lowering medication, is the first and only proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor to offer a monthly single-dose delivery option.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.